ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients’ device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN’s software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Sleep Tech Dominance | ResMed's market leadership in sleep apnea and respiratory care devices faces challenges from emerging treatments and renewed competition |
Financial Resilience | Explore ResMed's robust financial performance, with consistent revenue growth and strong earnings, despite looming market disruptions |
Innovation Pipeline | Delve into ResMed's strategic expansion beyond CPAP, leveraging AI and wearable technology to diversify its product portfolio |
Market Outlook | Analyst targets range from $180 to $250, reflecting varied perspectives on ResMed's ability to navigate pharmaceutical threats and maintain growth |
Metrics to compare | RMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRMDPeersSector | |
---|---|---|---|---|
P/E Ratio | 31.6x | 59.9x | −0.6x | |
PEG Ratio | 1.40 | −2.06 | 0.00 | |
Price/Book | 6.8x | 8.1x | 2.6x | |
Price / LTM Sales | 7.3x | 11.2x | 3.1x | |
Upside (Analyst Target) | 10.9% | 22.6% | 54.8% | |
Fair Value Upside | Unlock | −25.0% | 7.9% | Unlock |